HC Wainwright Issues Optimistic Estimate for CATX Earnings

Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Equities research analysts at HC Wainwright upped their Q2 2025 earnings per share estimates for shares of Perspective Therapeutics in a research report issued on Monday, March 31st. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.28) for the quarter, up from their prior estimate of ($0.29). HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Perspective Therapeutics' Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.32) EPS and FY2025 earnings at ($1.18) EPS.

A number of other brokerages also recently weighed in on CATX. Royal Bank of Canada cut their price target on shares of Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating for the company in a report on Thursday, March 27th. Lifesci Capital raised shares of Perspective Therapeutics to a "strong-buy" rating in a research note on Thursday, March 6th. Scotiabank initiated coverage on shares of Perspective Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price target on the stock. Brookline Capital Management upgraded Perspective Therapeutics to a "strong-buy" rating in a research report on Monday, March 10th. Finally, Truist Financial decreased their target price on Perspective Therapeutics from $21.00 to $10.00 and set a "buy" rating on the stock in a report on Monday. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Perspective Therapeutics has a consensus rating of "Buy" and a consensus target price of $13.22.

Perspective Therapeutics Trading Down 3.6 %

Shares of Perspective Therapeutics stock traded down $0.07 during trading on Thursday, hitting $1.74. The stock had a trading volume of 337,145 shares, compared to its average volume of 797,051. The business has a fifty day moving average of $2.73 and a two-hundred day moving average of $5.78. Perspective Therapeutics has a fifty-two week low of $1.62 and a fifty-two week high of $19.05.

Insider Activity at Perspective Therapeutics

In related news, CEO Johan M. Spoor bought 22,026 shares of the firm's stock in a transaction on Friday, March 28th. The stock was bought at an average price of $2.24 per share, with a total value of $49,338.24. Following the purchase, the chief executive officer now directly owns 59,383 shares of the company's stock, valued at approximately $133,017.92. This represents a 58.96 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Robert F. Williamson III purchased 38,145 shares of the company's stock in a transaction dated Monday, March 31st. The stock was bought at an average cost of $2.14 per share, for a total transaction of $81,630.30. Following the completion of the purchase, the director now directly owns 108,982 shares of the company's stock, valued at $233,221.48. The trade was a 53.85 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 115,696 shares of company stock valued at $256,344. Company insiders own 3.52% of the company's stock.

Institutional Trading of Perspective Therapeutics

A number of institutional investors have recently bought and sold shares of the company. FMR LLC raised its stake in shares of Perspective Therapeutics by 3,994.9% during the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company's stock worth $73,489,000 after purchasing an additional 5,370,392 shares in the last quarter. Millennium Management LLC bought a new position in Perspective Therapeutics during the fourth quarter valued at approximately $4,132,000. State Street Corp lifted its stake in Perspective Therapeutics by 119.6% in the third quarter. State Street Corp now owns 2,190,239 shares of the company's stock valued at $29,240,000 after acquiring an additional 1,192,812 shares during the last quarter. Octagon Capital Advisors LP grew its position in Perspective Therapeutics by 62.1% in the fourth quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company's stock worth $7,352,000 after acquiring an additional 882,528 shares in the last quarter. Finally, Affinity Asset Advisors LLC increased its stake in shares of Perspective Therapeutics by 160.0% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company's stock worth $4,147,000 after purchasing an additional 800,000 shares during the last quarter. Institutional investors and hedge funds own 54.66% of the company's stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.